CNN anchor Jake Tapper caught on hot mic during Trump, Putin coverage: 'Give me my show'
Tapper, who usually hosts his two-hour program "The Lead" from 5 p.m. to 7 p.m. EST from Washington, D.C., was live Friday in Alaska, when his colleague Anderson Cooper attempted to throw it back to him.
"I'm fine, just give me my show back," Tapper said, seemingly expressing his frustration while failing to realize he was live. The hot mic moment was shared on X by conservative NewsBusters managing editor Curtis Houck.
A smiling Cooper then quipped, "Show's back!"
Ooops CNN hot mic catches an angry Jake Tapper!! pic.twitter.com/VdA9c6mHqw
'Allison Cooper': Trump calls CNN anchor Anderson Cooper 'Allison' in rant
After the awkward exchange, Tapper welcomed Sen. Adam Schiff to the show, but the California Democrat couldn't hear the CNN host. "I think I lost you," Schiff said.
Tapper then told the audience that "we're having real comms problems today. I'm sorry about that. If anybody can hear me, let's go throw it back to New York."
At that point, Cooper again took over, saying "Okay, Jake, thanks very much."
USA TODAY reached out to reps for Cooper, Tapper and CNN for comment.
At the Alaska summit, Trump and Putin failed to achieve a major breakthrough in peace negotiations over Russia's war against Ukraine.
Tapper occasionally becomes frustrated during on-air coverage. In 2020, Tapper played Lara Trump's remarks at a "Women for Trump" 2020 campaign event about former President Joe Biden during her interview on "State of the Union."
"Every time he comes on stage and they turn to him, I'm like: 'Joe, can you get it out. Let's get the words out,'" Trump said. Tapper then asked, "How do you think it makes little kids with stutters feel when they see you make a comment like that?"
Trump then responded that she did not know Biden had a stutter, which was a well-documented disability of the then-presidential candidate.
"I think what we see on stage with Joe Biden, Jake, is very clearly a cognitive decline. That's what I'm referring to," Trump said.
Tapper then shut down the interview, telling Trump that she had "absolutely no standing to diagnose somebody's cognitive decline." In May, Tapper revealed that he had apologized to Trump about the incident.
That same month, Tapper and co-author Alex Thompson of Axios released a controversial book "Original Sin" that explored the physical and cognitive decline of Biden during his presidency.
The book received significant backlash from certain liberal and center corners of the political spectrum.
Contributing: James Powel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Antonia Hylton cited reporting from the summit that suggested Karoline Leavitt looked frightened after meeting with Putin.
MSNBC host Antonia Hylton has suggested that President Donald Trump's aides, particularly Press Secretary Karoline Leavitt, may have been 'frightened' by what they had witnessed during the president's meeting with Russian President Vladimir Putin. On Saturday night's episode of MSNBC's The Weekend: Primetime, Hylton spoke to former U.S. Ambassador to Russia Michael McFaul—an Obama appointee—about Trump's summit with Putin in Anchorage on Friday. 'A lot of the press corps that was there, they reported in the minutes and hours after the presser that they saw members of the administration, like Karoline Leavitt, look ashen, almost frightened after what they had seen behind closed doors. What did that indicate to you?' Hylton asked McFaul.
Yahoo
an hour ago
- Yahoo
Why Investors Were So Fired Up About First Solar Stock on Friday
Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool
New York Times
an hour ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
